The trial, registered under numbers NL6179 and NTR6326, was designed as a prospective non-randomised cluster study and enrolled one hundred adults between July 2018 and June 2023. Rather than randomising individual patients, the investigators assigned whole institutions to different care models: the University Medical Centre Groningen, a tertiary referral centre, delivered a structured goal-directed nutritional support protocol known as GDNS, while the Hospital Group Twente, a secondary hospital, provided usual care. This cluster design was chosen deliberately to minimise the risk that the intervention protocol would contaminate routine practice at a single site. Eligible patients were over eighteen years old, had histologically confirmed, previously untreated oesophageal cancer, and were scheduled for curative-intent chemoradiotherapy and surgery. Patients undergoing salvage oesophagectomy, those with cervical lymph node involvement or distant metastases, post-cricoid tumours, poor performance status, or an inability to complete questionnaires were excluded. Fifty patients were included in each arm.

The intervention itself was built on three technical pillars. First, each patient in the GDNS group was assigned a dedicated dietitian acting as a case manager, who monitored dietary intake continuously and performed all nutritional assessments from baseline onward. Second, energy requirements were measured rather than merely estimated: indirect calorimetry was performed in 88 percent of patients at baseline, complementing standard predictive equations, alongside the Patient Generated-Subjective Global Assessment. Third, nutritional support—oral nutritional supplements, enteral tube feeding, and parenteral nutrition where necessary—was provided proactively rather than reactively. Usual care, by contrast, involved dietitians at multiple locations who monitored weight and intake during chemoradiotherapy and initiated support when deemed necessary, with research nurses conducting assessments using the short form of the PG-SGA, but without routine recording of intake or measured energy expenditure.

The study’s primary endpoint was the change in appendicular skeletal muscle index, or ASMI, the mass of limb skeletal muscle normalised to squared height, expressed in kilograms per square metre. Because computed tomography, the reference standard for muscle quantification, was only systematically available in the intervention group, the researchers relied on bioelectrical impedance analysis using a Seca mBCA 525 device, applying Sergi’s validated prediction formula and cross-checking the estimates against two independent biomarkers: skeletal muscle area measured on abdominal CT scans at the third lumbar vertebra level, and urinary creatinine excretion from 24-hour collections. The correlations were convincing—bioelectrical ASMI tracked CT-derived skeletal muscle index with correlation coefficients rising from 0.48 at baseline to 0.96 at twelve months, and urinary creatinine correlated at 0.58 and 0.72 at baseline and one year, respectively. Measurements were taken at seven or more timepoints: baseline, one week and three to six weeks after the start of chemoradiotherapy, between radiation completion and surgery, at oesophagectomy, before discharge, and at three, six, and twelve months postoperatively.

The central finding is a distinctive decline-recovery-decline pattern in muscle mass that played out identically in shape across both groups. During chemoradiotherapy, ASMI fell by 2.53 percent in the GDNS group and 3.20 percent under usual care—a modest loss compared with the pooled figure of roughly minus 6.69 percent reported in meta-analyses of neoadjuvant therapy. Between the end of radiotherapy and surgery, muscle mass actually rebounded in both arms, gaining 0.95 percent with GDNS and 2.51 percent with usual care, consistent with a recovery window that prior prehabilitation research has also documented. Then, after oesophagectomy, the pattern reversed: by twelve months, ASMI had fallen by 5.75 percent in the intervention group and 7.09 percent under usual care. Notably, in the peri-operative window alone—the stretch from the preoperative visit to early recovery—the usual care group lost 4.88 percent of limb muscle while the GDNS group lost only 0.93 percent, the sole between-group comparison that reached nominal statistical significance (P = 0.038), although this signal dissolved after adjustment for confounders such as surgical duration, blood loss, and hospital stay.

Formal statistical modelling reinforced the picture of a real but statistically non-significant difference favouring the intervention. An analysis of covariance incorporating sex, age, smoking, body mass index, and complications found no significant between-group difference in relative ASMI change at any phase, and sensitivity analyses adding sepsis to the covariates confirmed the result. Generalised linear mixed-effects modelling, which best captured the non-linear trajectory with a random-intercept model containing a quadratic time term over a mean seventeen-week interval from baseline to surgery, likewise detected no intervention effect. The investigators had powered the study to detect a five percent improvement in muscle mass during chemoradiotherapy; the observed differences, though directionally consistent, fell short of that threshold. Reduced sample size—driven partly by attrition, with only 16 and 21 patients respectively completing the full twelve-month follow-up, and by the logistical strains of conducting research during the COVID-19 pandemic—likely constrained the study’s ability to confirm what the trends suggest.

Beyond the primary endpoint, the goal-directed approach left clearer fingerprints on other measures of nutritional status. Energy intake in the GDNS group rose from 23.4 to 28.0 kcal/kg and protein intake from 1.03 to 1.32 g/kg during chemoradiotherapy, values that closely match international ESPEN guideline targets of 25 to 30 kcal/kg and at least 1.0 to 1.5 g protein/kg. Body mass index declined less steeply during radiotherapy in the intervention group, and while waist circumference and fat mass index increased slightly under GDNS, they decreased under usual care. Urinary creatinine, a biochemical surrogate of total muscle mass, remained stable in the intervention group across the first six months but declined significantly under usual care—a between-group difference that did reach significance. Malnutrition defined by the GLIM criteria nonetheless rose in both arms during chemoradiotherapy, from 34.1 to 58.5 percent in GDNS and from 35.4 to a striking 85.4 percent under usual care, and quality of life, assessed with the EORTC QLQ-C30 questionnaire, was significantly better at the end of radiotherapy in the intervention group before recovering in both arms after surgery.

The study also surfaced uncomfortable truths about translating measured physiology into clinical targets. Although indirect calorimetry revealed that measured resting energy expenditure at baseline—1854 kcal on average—significantly exceeded the 1674 kcal predicted by standard equations, the measured targets were actually applied in clinical practice in only 22 percent of cases at baseline and 37.5 percent later in treatment, apparently reflecting dietitians’ habitual reliance on predictive equations and a blanket 30 percent physical-activity correction that overlooks interindividual variation. Surgical outcomes added further complexity: the GDNS group experienced longer operations, greater blood loss, longer hospital stays, and a higher rate of postoperative sepsis (19.4 versus 2.6 percent), which the authors attribute plausibly to a learning curve, since robot-assisted oesophagectomy was being introduced at the tertiary centre during the study while the secondary hospital had already mastered it. One-year overall and disease-free survival did not differ between the arms.

Set against the wider literature, the modest muscle loss observed in this trial is itself noteworthy. Previous cohorts of oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy have reported substantially larger declines, and the present figures are more comparable to those seen with neoadjuvant chemotherapy alone, hinting that both intensive support and improving usual care may contribute to attenuation. The findings also echo the growing consensus that nutrition alone cannot fully protect muscle: the PERFECT exercise trial found that resistance training preserved fat-free mass after oesophagectomy but was thwarted by inadequate postoperative protein intake, exactly the deficit the Dutch team observed between three and six months after surgery in their intervention group. The authors argue that this points squarely toward personalised, integrated interventions combining dietetics and physical therapy, with particular attention to the postoperative phase, where the steepest losses occurred in both arms.

Ultimately, the study delivers a measured verdict. A dedicated dietitian, calorimetry-based targets, and proactive tube feeding and supplementation produced better nutritional intake, more favourable body composition trends, and improved quality of life, and smaller—but not statistically significant—muscle loss during chemoradiotherapy and at one year after surgery. Survival was unchanged, and unexpected surgical complications in the intervention cohort cloud the risk-benefit calculus. What the trial establishes most firmly is the biological narrative: muscle mass in oesophageal cancer follows a predictable rhythm of loss during radiation, partial recovery before surgery, and renewed decline afterward, and the postoperative period is where the greatest opportunity for intervention still lies. For clinicians managing this notoriously catabolic disease, the message is that even intensive nutrition cannot be a substitute for a genuinely integrated, individualised recovery strategy.

Breast cancer treatment has witnessed unprecedented improvements in survival rates over recent decades, shifting the focus of oncological care toward not just prolonging life but enhancing the lived experience during treatment. Chemotherapy, despite its efficacy in targeting malignant cells, imposes significant physiological and psychological burdens, including fatigue, muscle atrophy, and emotional distress. These side effects can compromise patient outcomes and adherence to therapy. The new analysis addresses a critical knowledge gap: can patients safely and effectively incorporate exercise into their treatment regime to counter these adverse effects?

Previously, clinical guidelines and patient counseling commonly suggested initiating exercise post-treatment, largely because the impact of physical activity concurrent with chemotherapy remained insufficiently understood and sometimes viewed as risky. Patients frequently reported confusion or fear regarding whether movement could exacerbate symptoms or interfere with treatment efficacy. The systematic review and meta-analytic approach adopted by the research team shed light on this ambiguity by rigorously aggregating data from 21 randomized controlled trials encompassing over 3,000 women actively receiving chemotherapy for breast cancer.

What makes this study particularly robust is its inclusive examination of varied exercise modalities. Rather than isolating a singular intervention, it encompasses aerobic activities such as walking and cycling, strength or resistance training, and combined programs integrating both forms of exercise. Intriguingly, the meta-analysis revealed no superiority hierarchy; all forms produced significant, positive effects on patients’ quality of life metrics. This flexibility is medically and practically significant, as it enables personalized exercise prescriptions adapted to fluctuating energy levels and physical capacity, which are hallmark challenges during chemotherapy cycles.

The mechanistic underpinnings of how exercise confers these benefits during chemotherapy are complex and multifaceted. From a physiological standpoint, physical activity stimulates muscle protein synthesis and counters catabolic effects induced by cytotoxic agents. Aerobic conditioning enhances cardiovascular function, reducing fatigue and improving oxygen transport to tissues. In parallel, strength training helps preserve lean body mass critical for maintaining metabolic health and functional independence. Beyond the physical, engaging in regular movement modulates neuroendocrine pathways and inflammatory cytokines, attenuating mood disturbances and cognitive dysfunction commonly experienced during treatment.

LaShae D. Rolle, MPH, CPH, the study’s lead author and a predoctoral fellow, emphasized the paradigm shift in oncology care toward integrating supportive strategies as essential rather than ancillary. She noted that quality of life should be a central therapeutic objective throughout treatment, not an afterthought following completion of chemotherapy. This philosophy underlines a more holistic approach in cancer care. Furthermore, co-author Tracy Crane, Ph.D., RDN, highlighted that exercise need not be intimidating or prescriptive to the point of rigidity. Instead, safety, personalization, and realism are paramount, empowering patients to engage in movement aligned with their daily condition and preferences.

The study’s exclusive focus on women undergoing active chemotherapy distinctly separates it from research oriented toward cancer survivors post-treatment, addressing the unique challenges patients face during the intense, variable phases of chemotherapy. These challenges include fluctuating symptoms such as nausea, pain, and immunosuppression, which demand adaptable and responsive exercise regimens orchestrated in conjunction with clinical oversight. The authors advocate that exercise should be administered under professional guidance to optimize benefits while ensuring patient safety.

From an oncological clinical perspective, integrating exercise as a co-therapy may also favorably influence treatment adherence and potentially reduce dose reductions or delays often necessitated by debilitating side effects. The data suggest that exercise interventions can serve as a non-pharmacologic modality that complements cytotoxic and targeted therapies, enhancing patients’ physical resilience and psychological fortitude.

Moreover, the findings have implications for healthcare policy and cancer care frameworks globally. Incorporating exercise programs within treatment protocols could standardize supportive care practices, reinforcing the role of physical activity in managing treatment toxicity. Importantly, this could help bridge gaps in survivorship care planning and improve long-term survivorship outcomes by instilling physical activity habits during the most critical treatment phases.

The researchers also underscore that while exercise confers broad benefits, the individualized nature of cancer treatment necessitates tailored prescriptions sensitive to patient-specific variables such as age, cancer stage, comorbidities, and baseline fitness. This nuanced approach fosters adherence, reduces risk of injury, and maximizes therapeutic impact.

In conclusion, this landmark meta-analytic review decisively supports the integration of exercise into chemotherapy regimens for women with breast cancer, highlighting that movement—appropriately calibrated—can transform patient experiences and outcomes. This paradigm shift underscores exercise as a pivotal adjunct in comprehensive oncology care, moving physical activity from a peripheral recommendation to a cornerstone of therapeutic strategy.

Subject of Research: Exercise interventions and quality of life during chemotherapy in women with breast cancer
Article Title: The Impact of Exercise Interventions on Domains of Quality of Life in Women Diagnosed with Breast Cancers During Chemotherapy Treatment: A Meta-Analytics Review
News Publication Date: 25-Feb-2026
Web References: http://dx.doi.org/10.1016/j.lanhl.2026.100819
Image Credits: Sylvester Comprehensive Cancer Center
Keywords: Breast cancer, Physical exercise, Chemotherapy